Mirtazapine (Remeron) and Urinary Retention
Yes, mirtazapine can cause urinary retention, particularly in elderly males with benign prostatic hyperplasia (BPH), and should be used with extreme caution or avoided in this population.
Mechanism and Risk Profile
Mirtazapine acts as an antagonist at muscarinic receptors, which directly impairs bladder detrusor muscle contractility and increases urethral sphincter tone 1. This anticholinergic effect is the primary mechanism by which it causes urinary retention. The FDA labeling confirms mirtazapine's muscarinic receptor antagonism as part of its pharmacodynamic profile 1.
Clinical Evidence
The risk is particularly well-documented in vulnerable populations:
Elderly males with BPH: A 2025 case report demonstrated acute urinary retention occurring within 24 hours of mirtazapine initiation in a 70-year-old man with underlying BPH, requiring emergency catheterization 2. The authors emphasize that "the possibility of acute urinary retention caused by mirtazapine, particularly in patients with benign prostatic hyperplasia, cannot be ignored" 2.
General incidence: Systematic reviews show that antidepressants with anticholinergic properties cause voiding disorders at significantly higher rates than placebo (OR: 3.30; 95% CI: 1.90-5.72) 3. While this meta-analysis focused on tricyclics and SNRIs, mirtazapine's muscarinic antagonism places it in a similar risk category.
Observational data: Up to 10% of acute urinary retention episodes may be attributable to concomitant medication use, with drugs having anticholinergic activity being major culprits 4.
High-Risk Patient Identification
Screen for these risk factors before prescribing mirtazapine:
- Male gender with age >60 years
- Known BPH or baseline lower urinary tract symptoms (LUTS)
- Elevated post-void residual (PVR) urine volume (>150 mL is particularly concerning per urological guidelines) 5
- Concurrent use of other anticholinergic medications
- History of urinary retention
The AUA guidelines emphasize that men with elevated baseline PVR are at substantially higher risk for acute urinary retention when exposed to anticholinergic agents 6.
Management Algorithm
If urinary retention develops:
- Immediate intervention: Perform bladder catheterization for acute retention 4
- Discontinue or reduce mirtazapine dose immediately 2, 4, 7
- Monitor for resolution: Most cases improve within days of drug discontinuation 7, 8
- Consider alternative antidepressants: SSRIs have significantly lower rates of voiding dysfunction compared to agents with anticholinergic properties 3
Preventive approach in at-risk patients:
- Measure baseline PVR before initiating mirtazapine in elderly males
- If PVR >150 mL or symptomatic BPH exists, strongly consider alternative antidepressants (SSRIs preferred) 5, 3
- If mirtazapine is essential, start at lowest dose (7.5-15 mg) and monitor closely
- Educate patients to report any difficulty urinating immediately
Critical Pitfalls to Avoid
Do not dismiss new urinary symptoms as simply "BPH progression" in patients recently started on mirtazapine. The temporal relationship is key—symptoms appearing within days to weeks of drug initiation strongly suggest drug causation 2.
Do not assume all antidepressants carry equal urinary risk. SSRIs have substantially lower odds of voiding dysfunction compared to tricyclics, SNRIs, and mirtazapine 3. When urinary function is a concern, SSRIs are the safer choice.
Do not continue mirtazapine hoping symptoms will resolve spontaneously. Case reports consistently show that urinary retention persists until the drug is discontinued or dose-reduced 2, 7, 8.
Special Populations
In elderly patients, mirtazapine clearance is reduced by 40% in males and 10% in females, with elimination half-lives of 26-37 hours 1. This prolonged exposure increases anticholinergic burden and urinary retention risk. The combination of age-related pharmacokinetic changes and high BPH prevalence makes elderly males the highest-risk group 2, 4.